Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $17.63 Average Target Price from Brokerages

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has been assigned an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $17.63.

A number of analysts have recently weighed in on FOLD shares. Morgan Stanley dropped their price objective on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Jefferies Financial Group started coverage on shares of Amicus Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $18.00 price target for the company. Cantor Fitzgerald raised their price target on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, November 7th. Finally, Guggenheim raised their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th.

Insider Buying and Selling

In related news, CEO Bradley L. Campbell sold 7,901 shares of Amicus Therapeutics stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total transaction of $98,762.50. Following the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $11,083,175. The trade was a 0.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 30,401 shares of company stock valued at $352,038 over the last three months. Corporate insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Amicus Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in FOLD. American International Group Inc. increased its stake in shares of Amicus Therapeutics by 1.3% in the 1st quarter. American International Group Inc. now owns 143,034 shares of the biopharmaceutical company’s stock worth $1,685,000 after acquiring an additional 1,785 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in shares of Amicus Therapeutics by 7.8% during the first quarter. CANADA LIFE ASSURANCE Co now owns 100,538 shares of the biopharmaceutical company’s stock valued at $1,183,000 after purchasing an additional 7,304 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Amicus Therapeutics by 0.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,389,361 shares of the biopharmaceutical company’s stock worth $16,368,000 after purchasing an additional 12,003 shares in the last quarter. Silvercrest Asset Management Group LLC grew its stake in shares of Amicus Therapeutics by 4.5% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 374,958 shares of the biopharmaceutical company’s stock worth $4,417,000 after buying an additional 16,033 shares during the last quarter. Finally, Bayesian Capital Management LP purchased a new stake in shares of Amicus Therapeutics in the 1st quarter worth approximately $591,000.

Amicus Therapeutics Trading Up 0.9 %

Shares of FOLD stock opened at $9.96 on Tuesday. The business has a 50-day moving average of $10.75 and a 200 day moving average of $10.59. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. Amicus Therapeutics has a 1-year low of $9.02 and a 1-year high of $14.57. The stock has a market capitalization of $2.98 billion, a PE ratio of -29.29 and a beta of 0.68.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.